Xander Lee

Cooley advised Harvey, a legal artificial intelligence platform, on its $100 million Series C financing, which brings Harvey to a $1.5 billion valuation.

Cooley advised Foreseen Biotechnology – an emerging biotech company that pioneered a high-throughput integrated translational proteomics platform powered by an artificial intelligence-based data analytical system to accelerate the discovery of novel targets for therapeutics and diagnostics that are clinically relevant – on its exclusive global licensing agreement with Ipsen for FS001, an antibody-drug conjugate with first-in-class potential.

Cooley advised Yardi Systems, a large software corporation with offices worldwide, in connection with WeWork’s emergence from Chapter 11 and completion of WeWork’s global operational and financial restructuring.

Cooley advised Lacework, a data-driven cloud security company, on its definitive agreement to be acquired by Fortinet (Nasdaq: FTNT), the global cybersecurity leader driving the convergence of networking and security.

Cooley advised Structure Therapeutics (Nasdaq: GPCR), a global, clinical-stage biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, on its upsized $547.4 million underwritten public offering.